
CellCentric Completes $120 Million Series C Funding Round for Multiple Myeloma Treatment Inobrodib
Key Takeaways CellCentric’s $120 million Series C funding supports late-stage development of inobrodib, a novel oral p300/CBP inhibitor for multiple myeloma. Inobrodib’s mechanism targets MYC and IRF4 expression, addressing therapy resistance in …